Top Ten "Must Attend" Breakout Sessions at the 2011 BIO International Convention

  • Recommend
  • Tweet
  • Print
  • Email
Deck: 
What are some of the top breakout sessions this year?
Teaser: 

GEN's Editor-in-Chief John Sterling outlines his picks for the top ten "must attend" breakout sessions at the 2011 BIO International Convention.

John Sterling’s picks:
TOP TEN “MUST ATTEND” BREAKOUT SESSIONS

74 - Getting Approval for Drugs in an Ever-Increasing Risk-Averse World (Track: Achieving Regulatory Approval and Compliance) [2]
Monday, June 27
2:00 pm - 3:15 pm

  • Give insight on the changing regulatory environment and critical success factors for new applications.
  • Describe the challenges of a filing process from the company’s and regulator’s point of view.
  • Learn how to get a cell therapy product evaluated as a drug.

77 - Talking About Your Product in the New Age: Social Media and the Internet (Track: Achieving Regulatory Approval and Compliance)  [3]
Tuesday, June 28
3:45 pm - 5:00 pm

  • Understand current regulatory standards and policies related to dissemination of information outside of labeling.
  • Understand current venues for disseminating product information on the Internet and through social media.
  • Understand potential liability, and identify measures to avoid it.

90 - Rediscovering the Promise of Biomarkers (Track: Biomarkers)  [4]
Tuesday, June 28
8:30 am - 9:45 am

  • Learn about new models for international PPPs to reduce risk and cost for biomarker research.
  • Understand the regulatory challenges facing the biomarkers qualification and validation.
  • Explore how to work internationally to leverage resources for biomarker research.

198 - Crossing the Financing Gap? Alternative Strategies for Funding Biomedical Technologies for the Clinic (Track: Finance) [5] 
Monday, June 27
2:00 pm - 3:15 pm

  • Describe innovative strategies that leverage alternative sources of capital to enable development.
  • Discuss current financing for clinically related biotechnologies, including nontraditional sources.
  • Discover nondilutive NIH funding opportunities and resources that support early development.

98 - Personalized Medicine and Companion Diagnostics: The Changing Biopharma Industry Landscape (Track: Diagnostics and Personalized Medicine)  [6]
Thursday, June 30
8:30 am - 9:45 am

  • Develop an understanding of the personalized medicine landscape.
  • Interact with thought leaders in the industry.
  • Give audience the opportunity to follow up for potential collaborative initiatives.

174 - The Effect of a More Risk Averse Environment on Licensing Deals (Track: Business Development) [7] 
Monday, June 27
2:00 pm - 3:15 pm

  • Describe the current environment within licensing biopharma companies with regard to risk for in-licensed programs.
  • Indicate specific risk management strategies and their implications.
  • Give advice from licensees on how best to strategize with a licensing partner.

188 - The Changing BD Environment: Overcoming Our Past to Succeed in the Future (Track: Business Development) [8] 
Tuesday, June 28
2:00 pm - 3:30 pm

  • Explain the dynamics (type, economics, timing, roles) driving biotech/pharma collaborations.
  • Conceptualize novel approaches to biotech and pharma collaborations.
  • Identify key deal showstoppers from either a historical or novel transaction approach.

110 - Improving Innovation Through the Use of Social Networks (Track: Global Innovations & Markets)  [9]
Thursday, June 30, 2011
8:30 am - 9:45 am

  • Participants will appreciate how to manage risk of engaging on social networks.
  • Show how open networks may help solve big problems in innovation.
  • Explain strategic considerations necessary for social networking initiatives.

126 - The Vaccine Business Opportunity — Breakthrough Technologies for Preventing and Treating Disease (Track: Innovations in Vaccines)  [10]
Monday, June 27
3:45 pm - 5:00 pm

  • Identifying challenges and opportunities for vaccines in preventing infection and treating cancer.
  • Give the perpsective of big biotech and pharma in this field—both established and new players.
  • Describe the investor perspective on vaccines and which approaches are most likely to be funded.

141 - Safer, Faster, Cheaper: Changing Process Paradigms, Platforms and Products in Biomanufacturing (Track: Manufacturing of Biologics and Drugs) [11]
Thursday, June 30
8:30 am - 9:45 am

  • Describe the paradigm shift from handcrafted to mature process technologies in biomanufacturing.
  • Describe how the FDA’s initiatives have sped the adoption of process methods since 1997.
  • Demonstrate how the process controls enable faster, cheaper and safer biologics.
Thumbnail Image: 
image/jpeg iconJohn Sterling 014.jpg [12]
Hide Related Contenet: 
Show
Hide Date: 
Show
Show Author Info?: 
Show Author Info?
Embedded Video Thumb: 
image/jpeg iconJohn Sterling 014.jpg [13]